Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportOncology: Clinical Diagnosis

Y-90 microspheres treatment response monitoring: PET/CT or diagnostic MR ?

Uliyana Yankevich, Peter Faulhaber, Chaitra Badve and James ODonnell
Journal of Nuclear Medicine May 2015, 56 (supplement 3) 1335;
Uliyana Yankevich
1Radiology, University Hospitals Case Medical Center, Cleveland, OH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter Faulhaber
1Radiology, University Hospitals Case Medical Center, Cleveland, OH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chaitra Badve
1Radiology, University Hospitals Case Medical Center, Cleveland, OH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James ODonnell
1Radiology, University Hospitals Case Medical Center, Cleveland, OH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

1335

Objectives The intra-arterial administration of Y-90 microspheres is a new palliative treatment for unresectable liver malignancies. However, there is no widely accepted imaging protocol for treatment response monitoring. Our aim was to compare the accuracy of FDG-PET/CT and a standard-protocol liver MR in evaluating response to Y-90 microspheres embolisation.

Methods We evaluated 25 patients who underwent Y-90 microspheres embolisation (SIR-Spheres, Sirtex Medical Ltd., Sydney, Australia) for pathologically proven liver malignancy. Baseline imaging studies prior to treatment as well as post-treatment CT, MR, or PET/CT scans were reviewed. A subset of 4 patients had post-treatment MR and PET/CT scans not more than 1 mo apart. Both studies were examined in comparison to each other and against the results of long-term clinical or imaging follow-up to determine if PET/CT is more accurate than MR in defining treatment response and directing patient management.

Results 25 patients were treated with SIR-Spheres in our institution in the above time interval. 4 patients were treated for primary liver malignancy; the others had metastatic liver disease. All patients had diagnostic liver MR 4 to 8 weeks after the treatment. 4 patients also had FDG-PET/CT scan performed not more than 4 weeks apart from the MR. In 3 out of 4 patients, the MRI demonstrated grossly stable appearance of the liver when compared to pre-treatment imaging suggestive of stable liver disease, whereas PET/CT showed no hypermetabolic activity in the treated lesions consistent with no residual disease. None of these patients had liver disease recurrence in the next 22 months. In 1 patient, both modalities showed metastatic disease progression, which was confirmed by CT follow up 3 months later.

Conclusions FDG-PET/CT imaging may be a more accurate assessment of therapy response following Y-90 microspheres embolisation than liver MR; larger cohort of patients is currently under evaluation.

Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 56, Issue supplement 3
May 1, 2015
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Y-90 microspheres treatment response monitoring: PET/CT or diagnostic MR ?
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Y-90 microspheres treatment response monitoring: PET/CT or diagnostic MR ?
Uliyana Yankevich, Peter Faulhaber, Chaitra Badve, James ODonnell
Journal of Nuclear Medicine May 2015, 56 (supplement 3) 1335;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Y-90 microspheres treatment response monitoring: PET/CT or diagnostic MR ?
Uliyana Yankevich, Peter Faulhaber, Chaitra Badve, James ODonnell
Journal of Nuclear Medicine May 2015, 56 (supplement 3) 1335;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Oncology: Clinical Diagnosis

  • High detection performance and accurate staging of adrenal glands using state-of-the-art PET/CT
  • Baseline total lesion glycolysis by positron emission tomography/ computed tomography as a best prognostic parameter for patients with primary thyroid lymphoma
  • Diagnostic value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography for cutaneous lesions from extranodal natural killer/ T-cell lymphoma
Show more Oncology: Clinical Diagnosis

MTA I: GI-Colorectal & Liver Posters

  • Role of FDG PET-CT in prognostication of Hepatocellular carcinoma patients undergoing Transarterial Radioembolisation
  • Fusion PET/MRI Assessment of 18F-FDG PET-positive Lesions Comparing With PET/CT in Abdomen
  • Correlation of tumor size and metabolism with perfusion in hepatocellular carcinoma using dynamic contrast enhanced CT and F-18 FDG PET-CT
Show more MTA I: GI-Colorectal & Liver Posters

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire